Drugbank Logo

Showing drug card for Methsuximide (DB05246)

Legend: drug field target field enzyme field

for drugs
Version 2.5
Creation Date 2007-10-31 01:03:28
Update Date 2009-04-16 16:48:28
Primary Accession Number DB05246
Secondary Accession Number Not Available
Name Methsuximide
Drug Type
  • Approved
  • Small Molecule
Description Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. [Wikipedia]
Synonyms
  1. (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion
  2. 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine
  3. 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione
  4. 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione
  5. 1,3-Dimethyl-3-phenylsuccinimide
  6. Alpha-methyl-alpha-phenyl n-methyl succinimide
  7. Alpha-methylphensuximide
  8. Mesuximida [inn-spanish]
  9. Mesuximide
  10. Mesuximidum [inn-latin]
  11. Methsuximid
  12. Metosuccimmide [DCIT]
  13. Metsuccimide
  14. N,2-Dimethyl-2-phenylsuccinimide
  15. N-methyl-alpha-methyl-alpha-phenylsuccinimide
Brand Names
  1. Celontin
  2. Petinutin
Brand Mixtures Not Available
Chemical IUPAC Name 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
Chemical Formula C12H13NO2
Chemical Structure Structure
CAS Registry Number 77-41-8
InChI Identifier InChI=1/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
InChI Key AJXPJJZHWIXJCJ-UHFFFAOYAR
KEGG Drug Not Available
KEGG Compound Not Available
PubChem Compound 6476 Link Image
PubChem Substance 10394084 Link Image
ChEBI ID Not Available
PharmGKB ID PA450438 Link Image
HET ID Not Available
GenBank ID Not Available
Drug ID Number [DIN] 00022802 Link Image
RxList Link http://www.rxlist.com/cgi/generic/methsuximide.htm Link Image
PDRhealth Link Not Available
Wikipedia Link http://en.wikipedia.org/wiki/Methsuximide Link Image
FDA Label Not Available
Material Safety Data Sheet (MSDS) Not Available
Synthesis Reference Not Available
Average Molecular Weight 203.2371
Monoisotopic Molecular Weight 203.0946
State Solid
Melting Point 52.5 oC
Experimental Water Solubility Not Available Source: PhysProp
Predicted Water Solubility 2.13e+00 mg/mL Calculated using ALOGPS
Experimental LogP/Hydrophobicity Not Available Source: PhysProp
Predicted LogP 1.46 Calculated using ALOGPS
Experimental LogS Not Available
Predicted LogS -1.98 Calculated using ALOGPS
Experimental Caco2 Permeability Not Available
pKa/Isoelectric Point Not Available
Mass Spectrum Not Available
MOL File Show Link Image | Download Link Image
SDF File Show Link Image | Download Link Image
PDB File Show Link Image | Download Link Image
2D Structure
3D Structure
Experimental PDB ID Not Available
Isomeric SMILES CN1C(=O)C[C@](C)(C1=O)C1=CC=CC=C1
Canonical SMILES CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
Drug Category
  • Anticonvulsants
ATC Codes Not Available
AHFS Codes Not Available
Indication For the control of absence (petit mal) seizures that are refractory to other drugs.
Pharmacology Not Available
Mechanism of Action Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
Absorption Not Available
Toxicity Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.
Protein Binding Not Available
Biotransformation Not Available
Half Life 1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.
Dosage Forms
Form Route
Capsule Oral
Patient Information Show Link Image
Contraindications Show Link Image
Interactions Show Link Image
Drug Interactions Not Available
Food Interactions Not Available
Pathways Not Available
General References
  1. Besag FM, Berry DJ, Pool F: Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. [PubMed Link Image]
  2. Hurst DL: Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. [PubMed Link Image]
  3. Wikipedia Link Image
  4. RxList Link Image
Organisms Affected
  • Humans and other mammals

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.